We Are Crinetics
Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Read the Latest
March 19, 2024
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
Crinetics Pharmaceuticals reports positive topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.
March 12, 2024
Crinetics Announces Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Crinetics announces positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and carcinoid syndrome.
Pipeline
We support patients, endocrinologists, and healthcare providers by finding better therapies for endocrine diseases and endocrine oncology such as:
- Acromegaly
- Carcinoid syndrome
- Cushing’s disease
- Congenital adrenal hyperplasia (CAH)
- Hyperparathyroidism
- Polycystic kidney disease
- Graves’ disease
- TED
- Diabetes
- Obesity
- Hyperinsulinism
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Acromegaly (PATHFNDR-1)
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Acromegaly (PATHFNDR-1)